Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01475760 · ClinicalTrials.gov registry record · NA

A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

A NA study of Chronic Kidney Disease, sponsored by Denver Nephrologists, P.C..

Completed
Registry status
NA
Development phase
167
Enrollment target
4
Study locations

NCT01475760: Completed NA study of Chronic Kidney Disease, sponsored by Denver Nephrologists, P.C..

NCT01475760 is a NA study of Chronic Kidney Disease that has completed, run by Denver Nephrologists, P.C.. The registered enrollment target is 167 participants, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01475760, a NA study of Chronic Kidney Disease, has completed, sponsored by Denver Nephrologists, P.C..

COMPLETED
Registry status
NA
Development phase
167 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to determine the efficacy of chitosan chewing gum (K2CG) in reducing serum phosphorus in subjects with chronic kidney disease.

Primary Outcome

Change in serum phosphorus from baseline to mean of values during 2 week active chewing period in patients with CKD not on dialysis

Conditions Studied

Interventions

  • OTHER K2CG chewing gum (20mg chitosan)
  • OTHER K2CG chewing gum (60mg chitosan)

Study Locations (4)

Arizona

  • Southwest Clinical Reserach Institute, LLC - Tempe

Colorado

  • Denver Nephrologists, PC - Denver

Idaho

  • Pacific Renal Research Institute - Meridian

Texas

  • Renal Associates, PA - San Antonio

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2011-11
Est. Completion 2012-03
Phase NA
Denver Nephrologists, P.C.

7 total trials

What the finished NCT01475760 record still lists

NCT01475760 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which K2CG chewing gum (20mg chitosan) is the first listed.

NCT01475760 reports a single indexed study location in Arizona, Colorado, Idaho.

Frequently Asked Questions

What is clinical trial NCT01475760 about?

NCT01475760 is a clinical study titled "A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease". The purpose of this study is to determine the efficacy of chitosan chewing gum (K2CG) in reducing serum phosphorus in subjects with chronic kidney disease.

What is the current status of trial NCT01475760?

This trial is currently completed. It is a NA study. The enrollment target is 167 participants. The study started on 2011-11. Estimated completion is 2012-03.

What conditions does trial NCT01475760 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT01475760?

The interventions under investigation include: K2CG chewing gum (20mg chitosan) (OTHER), K2CG chewing gum (60mg chitosan) (OTHER).

Who is sponsoring clinical trial NCT01475760?

This trial is sponsored by Denver Nephrologists, P.C., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01475760 being conducted?

This trial has 4 study locations across Arizona, Colorado, Idaho, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01475760's enrollment target sits among peer trials

167 42nd of 101 higher than 60 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04248283 · 167 participants · NA

    Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

  • NCT04552509 · 167 participants · NA

    TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

  • NCT05516277 · 167 participants · NA

    Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01475760, the US trial registry maintained by the National Library of Medicine. NCT01475760 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.